Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that dMMR status confers therapeutic sensitivity to Pembrolizumab in patients with Colorectal Adenocarcinoma.
This statement is based on a regulatory approval from the Health Service Executive:
First-line treatment of metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in adults